Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

ImmunityBio, Inc.

NASDAQ: IBRX · Life Sciences · 6 alerts · CIK 1326110

Share price
$5.98Close, Nov 16
Market cap
$6.36B
Shares outstanding
1.06BLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All ImmunityBio, Inc. filings on SEC EDGAR ↗

7:53 AM ET 10-Q
Financial Results

ImmunityBio Q3 2026 Results: Net Loss of $185M, Loss Widens

ImmunityBio reported total assets of $609.4 million as of September 30, 2026, an increase from $501.9 million at year-end 2025, driven primarily by a rise in marketable securities. The company maintains a significant stockholders' deficit and continues to operate as a large accelerated filer following the commercial launch of its approved product, ANKTIVA.

Key figure
Net loss $185M
7:40 AM ET 8-K
Financial Results

ImmunityBio Financial Results

ImmunityBio reported Q3 2026 net product revenue of $48.7 million, a 53% increase year-over-year, driven by the adoption of ANKTIVA in the U.S. The company also highlighted a recent FDA label expansion for ANKTIVA and positive topline results from its QUILT-2.005 trial in BCG-naïve bladder cancer patients.

Term
Q3 2026
6:34 AM ET 8-K
Clinical Trial Data

ImmunityBio Clinical Trial Data

ImmunityBio announced that its QUILT-2.005 trial of ANKTIVA plus BCG met its primary efficacy endpoint in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC). The combination therapy showed a statistically significant improvement in efficacy compared to BCG alone, and the company plans to submit a supplemental Biologics License Application (sBLA) to the FDA by year-end 2026.

5:19 PM ET 8-K
Regulatory Approval

ImmunityBio Regulatory Approval

The FDA has expanded the approved indication for ImmunityBio's ANKTIVA in combination with BCG to include patients with BCG-unresponsive NMIBC with papillary-only tumors. This follows the initial April 2024 approval and broadens the addressable patient population to include all patients with BCG-unresponsive NMIBC, a group that represents approximately 85% of the NMIBC population.

6:06 PM ET Form 4
Insider Selling

ImmunityBio Insider Barry J. Simon Sells $269K of Stock

Barry J. Simon sold 25,000 shares of ImmunityBio, Inc. at $10.75 a share, worth $269K in total on Oct 5, 2026. Shares held after the trade: 2,777,788 (-0.9%).

Value
$269K
Shares
25,000
Price
$10.75
Holding change
-0.9%
Trade date
Oct 5, 2026
6:06 PM ET Form 4
Insider Selling

ImmunityBio Insider Cheryl Cohen Sells $851K of Stock

Cheryl Cohen sold 81,056 shares of ImmunityBio, Inc. at $10.50 a share, worth $851K in total on Oct 2, 2026. Shares held after the trade: 100,309 (-44.7%).

Value
$851K
Shares
81,056
Price
$10.50
Holding change
-44.7%
Trade date
Oct 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.